A Durham biotechnology company has seen its stock price plummet over the past few days amid a stock offering and a media ...
With this funding, Entvin plans to expand its artificial intelligence capabilities and accelerate customer acquisition ...
Clearance of Vykat unlocks what analysts anticipate will be a lucrative market opportunity for Soleno Therapeutics.
The agency OK’d an artificial vessel to restore blood flow in patients, even though its own scientists flagged questionable ...
The FDA recently approved the first treatment in nearly 30 years for acute stroke, and the agency also approved a novel drug ...
Pharmaceutical firms may consult with health authorities individually to speed up process under streamlined drug approval ...
Dr. Laura Niklason, President and CEO of Humacyte, Inc. (NASDAQ:HUMA), responded to a New York Times (NYSE:NYT) article that questioned the FDA’s approval of Symvess for commercial sales earlier this ...
Proposals to eliminate the self-affirmed GRAS pathway have sent shockwaves through the food industry. But what do they mean ...
The FDA launches sweeping changes to food safety rules that could transform grocery aisles nationwide as untested ingredients ...
The U.S. health secretary has vowed to close an FDA loophole that has allowed food companies to self-police the safety of new ...
15d
GlobalData on MSNUFlex receives FDA approval for recycled polyethylene in food packagingThe move marks an advancement in reducing plastic waste and assisting global brands in achieving their sustainability ...
Shares of Tonix Pharmaceuticals are pulling back 12.7% during Thursday's session. The stock is pulling back following a regulatory update on its experimental fibromyalgia treatment, TNX-102 SL.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results